Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shingrix
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Shingrix is a non-live, recombinant subunit vaccine developed by GSK for the prevention of herpes zoster (shingles) and postherpetic neuralgia in adults. It consists of the Varicella Zoster Virus (VZV) glycoprotein E (gE) antigen produced in Chinese Hamster Ovary cells, combined with the AS01B adjuvant system. The AS01B adjuvant is composed of 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and a saponin (QS-21) in a liposomal formulation, which enhances the T-cell mediated immune response. Shingrix is typically administered as a two-dose intramuscular series and has demonstrated high efficacy and long-term persistence of immune response in older adults. It is also approved for use in adults who are at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy.
- Brand names
- Shingrix
- Other names
- Zoster Vaccine Recombinant, AdjuvantedRZVRecombinant Zoster Vaccine
02
Targets
TLR4 (Toll-like receptor 4)gE (VZV glycoprotein E)
Beyond the preview
Go deeper on Shingrix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shingrix.